Cellceutix Corporation:製薬企業の製品開発パイプライン分析2014

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC04963CDB)
◆英語タイトル:Cellceutix Corporation - Product Pipeline Review - 2014
◆発行会社/調査会社:Global Markets Direct
Single UserUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Cellceutix Corporation:製薬企業の製品開発パイプライン分析2014]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Cellceutix Corporation – Product Pipeline Review – 2014


Global Markets Direct’s, ‘Cellceutix Corporation – Product Pipeline Review – 2014’, provides an overview of the Cellceutix Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cellceutix Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of Cellceutix Corporation including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cellceutix Corporation’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Cellceutix Corporation’s pipeline products

Reasons to buy

- Evaluate Cellceutix Corporation’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cellceutix Corporation in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cellceutix Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cellceutix Corporation and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cellceutix Corporation
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cellceutix Corporation and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Cellceutix Corporation Snapshot 6
Cellceutix Corporation Overview 6
Key Information 6
Key Facts 6
Cellceutix Corporation – Research and Development Overview 7
Key Therapeutic Areas 7
Cellceutix Corporation – Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products – Monotherapy 15
Cellceutix Corporation – Pipeline Products Glance 16
Cellceutix Corporation – Clinical Stage Pipeline Products 16
Cellceutix Corporation – Early Stage Pipeline Products 18
Cellceutix Corporation – Drug Profiles 23
brilacidin 23
Kevetrin 25
KM-133 28
CTIX-1278 30
KM-277 31
KM-278 32
KM-3174 33
KM-362 34
KM-391 35
KM-732 37
PMX-0196 38
PMX-0231 39
PMX-0243 41
PMX-10072 43
PMX-10098 44
PMX-1207 45
PMX-1241 46
PMX-1278 47
PMX-1405 48
PMX-1408 49
PMX-1502 50
PMX-20005 51
PMX-207 52
PMX-225 53
PMX-30016 54
PMX-496 55
PMX-504 56
PMX-519 57
PMX-611 58
PMX-647 59
PMX-70004 60
PMX-70008 61
PMX-835 62
PMX-100 63
PMX-10070 64
PMX-1014 65
PMX-1045 66
PMX-1056 67
PMX-1057 68
PMX-1090 69
PMX-1091 70
PMX-1094 71
PMX-1099 72
PMX-1102 73
PMX-1142 74
PMX-1363 75
PMX-1424 76
PMX-1442 77
PMX-1445 78
PMX-1467 79
PMX-1488 80
PMX-1533 81
PMX-1547 82
PMX-1555 83
PMX-1560 84
PMX-1570 85
PMX-1572 86
PMX-1573 87
PMX-1576 88
PMX-1591 89
PMX-1625 90
PMX-183 91
PMX-223 92
PMX-229 93
PMX-247 94
PMX-255 95
PMX-30024 96
PMX-30053 97
PMX-520 98
PMX-633 99
PMX-668 100
PMX-693 101
PMX-728 102
PMX-741 103
PMX-843 104
PMX-868 105
Cellceutix Corporation – Pipeline Analysis 106
Cellceutix Corporation – Pipeline Products by Target 106
Cellceutix Corporation – Pipeline Products by Route of Administration 107
Cellceutix Corporation – Pipeline Products by Molecule Type 108
Cellceutix Corporation – Pipeline Products by Mechanism of Action 109
Cellceutix Corporation – Recent Pipeline Updates 110
Cellceutix Corporation – Dormant Projects 138
Cellceutix Corporation – Locations And Subsidiaries 139
Head Office 139
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 141
Disclaimer 141

List of Tables
Cellceutix Corporation, Key Information 11
Cellceutix Corporation, Key Facts 11
Cellceutix Corporation - Pipeline by Indication, 2014 14
Cellceutix Corporation - Pipeline by Stage of Development, 2014 19
Cellceutix Corporation - Monotherapy Products in Pipeline, 2014 20
Cellceutix Corporation - Phase II, 2014 21
Cellceutix Corporation - Phase I, 2014 22
Cellceutix Corporation - Preclinical, 2014 23
Cellceutix Corporation - Discovery, 2014 25
Cellceutix Corporation - Pipeline by Target, 2014 111
Cellceutix Corporation - Pipeline by Route of Administration, 2014 112
Cellceutix Corporation - Pipeline by Molecule Type, 2014 113
Cellceutix Corporation - Pipeline Products by Mechanism of Action, 2014 114
Cellceutix Corporation - Recent Pipeline Updates, 2014 115
Cellceutix Corporation - Dormant Developmental Projects,2014 143

List of Figures
Cellceutix Corporation - Pipeline by Top 10 Indication, 2014 13
Cellceutix Corporation - Pipeline by Stage of Development, 2014 19
Cellceutix Corporation - Monotherapy Products in Pipeline, 2014 20
Cellceutix Corporation - Pipeline by Top 10 Target, 2014 111
Cellceutix Corporation - Pipeline by Top 10 Route of Administration, 2014 112
Cellceutix Corporation - Pipeline by Top 10 Molecule Type, 2014 113
Cellceutix Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014 114

*** 免責事項 ***

※当市場調査資料(GMDHC04963CDB )"Cellceutix Corporation:製薬企業の製品開発パイプライン分析2014" (英文:Cellceutix Corporation - Product Pipeline Review - 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。